HR 1492 · in committee · significant
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
- healthcare
What this bill does
- This bill extends the time period required before drug products can have their prices negotiated under Medicare from 7 years to 11 years.
- Drug manufacturers and Medicare patients are affected, as the change delays when certain medications become eligible for price negotiations.
- The change applies retroactively and takes effect when the Medicare Drug Price Negotiation Program begins in 2026.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might extending the negotiation period from 7 to 11 years affect drug prices for Medicare patients during those additional four years?
- 02
What evidence supports that delaying price negotiations by four years benefits drug manufacturers' ability to recoup research and development costs?
- 03
Should biologic drugs receive the same negotiation timeline as small-molecule drugs, or do their development costs and complexities justify different periods?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-NC-3
Gregory F. Murphy
Citizen cosponsors
0
In Congress
67/ 435
House Reps cosponsoring
Introduced 2025-02-21
Joining the bill
Richard Hudson
R-NC-9 · original
Donald G. Davis
D-NC-1 · original
Claudia Tenney
R-NY-24
Neal P. Dunn
R-FL-2
Carol D. Miller
R-WV-1
Tim Moore
R-NC-14
Vern Buchanan
R-FL-16
Thomas H. Kean, Jr.
R-NJ-7
Mariannette Miller-Meeks
R-IA-1
Dan Crenshaw
R-TX-2
Nicole Malliotakis
R-NY-11
Beth Van Duyne
R-TX-24
+ 55 more
Legislative timeline
2025-02-21 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-21 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-21 · IntroReferral
Introduced in House
2025-02-21 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.